Advertisement

Outcomes with IV tenecteplase and IV alteplase for acute ischemic stroke with or without thrombectomy in real-world settings in the United States

      Abstract

      Background and Purpose

      Although many stroke centers in United States are using intravenous (IV) tenecteplase (TNK) for acute ischemic stroke patients, there is paucity of comparative data between IV TNK and IV alteplase from real-world settings.

      Materials and Methods

      We analyzed the data from 122 healthcare facilities in Cerner Real World Data and included patients admitted between February 2016 to April 2022 to determine the effect of IV TNK (compared with IV alteplase) on occurrence of two outcomes in acute ischemic stroke patients stratified by use of thrombectomy: non-routine discharge or death, and intracranial hemorrhage after adjusting for potential confounders.

      Results

      Among 30,643 acute ischemic stroke patients analyzed, 29,480 (96.2%) and 1,163 (3.8%) patients received IV alteplase and IV TNK, respectively. The proportion of patients who received thrombectomy was significantly higher among patients who received IV TNK compared with those who received IV alteplase (16.7% versus 11.0%, p<0.001). Occurrence of intracranial hemorrhage was more common among patients treated with IV TNK in acute ischemic stroke patients who did not receive thrombectomy (7.9% versus 5.1%, p<0.001) but not in those who received thrombectomy (20.1% versus 16.8%, p = 0.234). In the logistic regression analysis, patients treated with IV TNK who did not receive thrombectomy were at higher risk of intracranial hemorrhage (OR, 1.34, 95% CI 1.05-1.72, p = 0.02) after adjusting for age (age strata), gender, race/ethnicity, hypertension, diabetes mellitus, atrial fibrillation, hyperlipidemia, malignancy, nicotine dependence, previous ischemic stroke, previous transient ischemic attack, previous intracerebral hemorrhage, previous subarachnoid hemorrhage, previous acute myocardial infarction, atherosclerosis of aorta, previous AKI, congestive heart failure, peripheral vascular disease, and hospital type, aphasia, hemiplegia, neglect, somnolence, stupor and coma, dysphagia, and homonymous hemianopsia. There was no difference in the rate of non-routine discharge or death between patients treated with IV TNK and those treated with IV alteplase in the multivariate analyses.

      Conclusions

      In an analysis of real-world data, IV TNK was associated with higher rates of intracranial hemorrhage compared with IV alteplase in patients with acute ischemic stroke who did not undergo thrombectomy.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Stroke and Cerebrovascular Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Tanswell P
        • Modi N
        • Combs D
        • Danays T.
        Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.
        Clin Pharmacokinet. 2002; 41 (Epub 2002/11/28PubMed PMID: 12452736): 1229-1245https://doi.org/10.2165/00003088-200241150-00001
        • Burgos AM
        • Saver JL.
        Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke: meta-analysis of 5 randomized trials.
        Stroke. 2019; 50 (Epub 2019/07/19PubMed PMID: 31318627): 2156-2162https://doi.org/10.1161/STROKEAHA.119.025080
        • Campbell BCV
        • Mitchell PJ
        • Churilov L
        • Yassi N
        • et al.
        Tenecteplase versus alteplase before thrombectomy for ischemic stroke.
        N Engl J Med. 2018; 378 (Epub 2018/04/26PubMed PMID: 29694815): 1573-1582https://doi.org/10.1056/NEJMoa1716405
        • Powers WJ
        • Rabinstein AA
        • Ackerson T
        • Adeoye OM
        • et al.
        Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.
        Stroke. 2019; 50: e344-e418https://doi.org/10.1161/STR.0000000000000211
        • Deeds SI
        • Barreto A
        • Elm J
        • Derdeyn CP
        • Berry S
        • Khatri P
        • Moy C
        • Janis S
        • Broderick J
        • Grotta J
        • Adeoye O
        The multiarm optimization of stroke thrombolysis phase 3 acute stroke randomized clinical trial: Rationale and methods.
        Int J Stroke. 2021; 16 (Epub 2020/12/11PubMed PMID: 33297893): 873-880https://doi.org/10.1177/1747493020978345
        • Warach SJ
        • Dula AN
        • Milling TJ
        Tenecteplase thrombolysis for acute ischemic stroke.
        Stroke. 2020; 51: 440-3451
        • Putaala J
        • Saver JL
        • Nour M
        • Kleindorfer D
        • McDermott M
        • et al.
        Should Tenecteplase be given in clinical practice for acute ischemic stroke thrombolysis?.
        Stroke. 2021; 52: 3075-3080
        • Katsanos AH
        • Psychogios K
        • Turc G
        • Sacco S
        • de Sousa DA
        • De Marchis GM
        • Palaiodimou L
        • Filippou DK
        • Ahmed N
        • Sarraj A
        • Menon BK
        • Tsivgoulis G.
        Off-label use of tenecteplase for the treatment of acute ischemic stroke: a systematic review and meta-analysis.
        JAMA Netw Open. 2022; 5 (PMID: 35357458)e224506https://doi.org/10.1001/jamanetworkopen.2022.4506
        • Qureshi AI
        • Baskett WI
        • Huang W
        • et al.
        Facilitating the study of relationships between COVID-19 and cardiovascular health outcomes using cerner Real-World COVID-19 deidentified dataset.
        HealthCare Res J. 2020; 1: 17-28
        • Qureshi AI
        • Baskett WI
        • Huang W
        • Shyu D
        • Myers D
        • Raju M
        • Lobanova I
        • Suri MFK
        • Naqvi SH
        • French BR
        • Siddiq F
        • Gomez CR
        • Shyu CR.
        Acute ischemic stroke and COVID-19: an analysis of 27,676 patients.
        Stroke. 2021; 52 (Epub 2021 Feb 4. PMID: 33535779; PMCID: PMC7903982): 905-912https://doi.org/10.1161/STROKEAHA.120.031786
        • Qureshi AI
        • Baskett WI
        • Huang W
        • et al.
        Utilization and outcomes of acute revascularization treatments in ischemic stroke patients with SARS-CoV-2 infection.
        J Stroke Cerebrovasc Dis. 2022; 31 (PMID: 34689049; PMCID: PMC8498748)106157https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.106157
        • Marić I
        • Oskotsky T
        • Kosti I
        • et al.
        Decreased mortality rate among COVID-19 patients prescribed statins: data from electronic health records in the US.
        Front Med. 2021; 8 (Published 2021 Feb 3)639804https://doi.org/10.3389/fmed.2021.639804
        • Qureshi AI
        • Chaudhry SA
        • Sapkota BL
        • et al.
        Discharge destination as a surrogate for Modified Rankin Scale defined outcomes at 3- and 12-months poststroke among stroke survivors.
        Arch Phys Med Rehabil. 2012; 93 (e1401): 1408-1413
        • Warach SJ
        • Miley JT
        • Manzure M
        • Samantha M
        • et al.
        Results of a prospective observational cohort study of tenecteplase as standard of care stroke thrombolytic.
        Stroke. 2021; 52 (AP2–AP2)
        • Zhong CS
        • Beharry J
        • Salazar D
        • Smith K
        • Withington S
        • Campbell BCV
        • Wilson D
        • Le Heron C
        • Mason D
        • Duncan R
        • et al.
        Routine use of tenecteplase for thrombolysis in acute ischemic stroke.
        Stroke. 2021; 52: 1087-1090https://doi.org/10.1161/STROKEAHA.120.030859
        • Muir KW.
        Should tenecteplase replace alteplase for acute thrombolysis?.
        Stroke. 2021; 52: 1091-1093
        • Qureshi AI
        • Singh B
        • Huang W
        • Du Z
        • Lobanova I
        • Liaqat J
        • Siddiq F.
        Mechanical thrombectomy in acute ischemic stroke patients performed within and outside clinical trials in the United States.
        Neurosurgery. 2020; 86 (PMID: 31670379): E2-E8https://doi.org/10.1093/neuros/nyz359
        • Springer MV
        • Labovitz DL
        • Hochheiser EC.
        Race-ethnic disparities in hospital arrival time after ischemic stroke.
        Ethn Dis. 2017; 27: 125-132https://doi.org/10.18865/ed.27.2.125
        • Nagaraja N
        • Olasoji EB
        • Patel UK.
        Sex and racial disparity in utilization and outcomes of t-PA and thrombectomy in acute ischemic stroke.
        J Stroke Cerebrovasc Dis. 2020; 29 (Epub 2020 Jun 30. PMID: 32807414)104954https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104954
        • Saber H
        • Navi BB
        • Grotta JC
        • Kamel H
        • et al.
        Real-world treatment trends in endovascular stroke therapy.
        Stroke. 2019; 50: 683-689
        • Alhajji M
        • Kawsara A
        • Alkhouli M.
        Validation of acute ischemic stroke codes using the international classification of diseases tenth revision.
        Am J Cardiol. 2020; 125: 1135
        • Zachrison KS
        • Li S
        • Reeves MJ
        • et al.
        Strategy for reliable identification of ischaemic stroke, thrombolytics and thrombectomy in large administrative databases.
        Stroke Vasc Neurol. 2020;
        • Hassan AE
        • Chaudhry SA
        • Grigoryan M
        • et al.
        National trends in utilization and outcomes of endovascular treatment of acute ischemic stroke patients in the mechanical thrombectomy era.
        Stroke. 2012; 43: 3012-3017